Sandoz vs Zhejiang Huahai Pharmaceutical: why the prices moved differently

Weekly · monthly · quarterly news summaries, side by side in time

Sandoz Group AG (SDZ.SW)

Q3 202622 Jul – 11 Sep 2026

▲3▼1

Sandoz bets big on biosimilars as US tariff threat looms

US 100% generic tariff threat Trump threatened 100% tariffs on generic medicines, a direct risk to Sandoz's low-margin generics business. Its CEO warned tariffs would not bring production to the US and could disrupt supply of vital medicines, weighing on the shares.
A major policy threat to Sandoz's core generics business and a real counterweight to the positive news.
Strong H1 results and raised margin guidance First-half sales rose 10% to $5.76bn, with biosimilars up 25% and now a third of sales. Profit margins expanded and full-year margin guidance was raised, showing the biosimilar bet is paying off and supporting the shares.
Hard financial results that confirm the growth story and underpin the stock.
Bio100 strategy and pipeline expansion Sandoz unveiled Bio100, aiming to lead biosimilars by 2040 with over 100 products and to more than double sales in a decade. It added a Henlius partnership worth up to $322m and a $300m Slovenia plant, giving investors a long-term growth plan.
The strategy and pipeline deals set the long-term direction that drives the investment case.
New market approvals and Thailand talks Brazil approved Sandoz's semaglutide diabetes drug Owozy for launch in a $1.8bn market, and Thailand plans a cooperation deal within weeks to draw Sandoz investment. Both widen its reach, though near-term financial impact is limited.
Shows geographic expansion that adds future sales, a smaller but genuine positive driver.

August 202622 Jul – 11 Sep 2026

▲3▼1

Sandoz bets big on biosimilars as US tariff threat looms

US 100% generic tariff threat Trump threatened 100% tariffs on generic medicines, a direct risk to Sandoz's low-margin generics business. Its CEO warned tariffs would not bring production to the US and could disrupt supply of vital medicines, weighing on the shares.
A major policy threat to Sandoz's core generics business and a real counterweight to the positive news.
Strong H1 results and raised margin guidance First-half sales rose 10% to $5.76bn, with biosimilars up 25% and now a third of sales. Profit margins expanded and full-year margin guidance was raised, showing the biosimilar bet is paying off and supporting the shares.
Hard financial results that confirm the growth story and underpin the stock.
Bio100 strategy and pipeline expansion Sandoz unveiled Bio100, aiming to lead biosimilars by 2040 with over 100 products and to more than double sales in a decade. It added a Henlius partnership worth up to $322m and a $300m Slovenia plant, giving investors a long-term growth plan.
The strategy and pipeline deals set the long-term direction that drives the investment case.
New market approvals and Thailand talks Brazil approved Sandoz's semaglutide diabetes drug Owozy for launch in a $1.8bn market, and Thailand plans a cooperation deal within weeks to draw Sandoz investment. Both widen its reach, though near-term financial impact is limited.
Shows geographic expansion that adds future sales, a smaller but genuine positive driver.

Latest22 Jul – 11 Sep 2026

▲3▼1

Sandoz bets big on biosimilars as US tariff threat looms

US 100% generic tariff threat Trump threatened 100% tariffs on generic medicines, a direct risk to Sandoz's low-margin generics business. Its CEO warned tariffs would not bring production to the US and could disrupt supply of vital medicines, weighing on the shares.
A major policy threat to Sandoz's core generics business and a real counterweight to the positive news.
Strong H1 results and raised margin guidance First-half sales rose 10% to $5.76bn, with biosimilars up 25% and now a third of sales. Profit margins expanded and full-year margin guidance was raised, showing the biosimilar bet is paying off and supporting the shares.
Hard financial results that confirm the growth story and underpin the stock.
Bio100 strategy and pipeline expansion Sandoz unveiled Bio100, aiming to lead biosimilars by 2040 with over 100 products and to more than double sales in a decade. It added a Henlius partnership worth up to $322m and a $300m Slovenia plant, giving investors a long-term growth plan.
The strategy and pipeline deals set the long-term direction that drives the investment case.
New market approvals and Thailand talks Brazil approved Sandoz's semaglutide diabetes drug Owozy for launch in a $1.8bn market, and Thailand plans a cooperation deal within weeks to draw Sandoz investment. Both widen its reach, though near-term financial impact is limited.
Shows geographic expansion that adds future sales, a smaller but genuine positive driver.

Zhejiang Huahai Pharmaceutical Co Ltd (600521.CG)

Q3 202624 Jul – 7 Oct 2026

▲4

Huahai's profit surges on API growth, procurement wins, and US recovery

Q1-Q3 profit forecast up 170-190% Huahai expects net profit for the first three quarters of 2026 to jump 170%-190% to 1.03-1.10 billion yuan, driven by API market expansion, domestic procurement share gains, and a turnaround in US finished drug sales. This directly boosts investor confidence and the stock's earnings outlook.
This is the biggest new financial catalyst, showing a sharp profit increase that likely drives the stock price up.
Reciceptimab approved for market Huahai's first-in-class IL-36R antibody Reciceptimab (Huayijing) received marketing approval in China for generalized pustular psoriasis. This strengthens its innovative drug pipeline and opens a new revenue stream, supporting long-term growth and valuation.
A new drug approval is a concrete pipeline win that can lift future earnings and investor sentiment.
Won bids for 4 products in national procurement Huahai won bids for four products in China's 12th national drug procurement, three of which were newly approved in Q2 2026. Winning these bids helps quickly expand domestic hospital sales and market share, though price cuts are typical in such programs.
Procurement wins directly boost domestic sales volume and are a key growth driver cited in the profit forecast.
US tariff refunds and HB0043 trial approval Huahai received over $10 million in US IEEPA tariff refunds, adding a one-time profit boost. Separately, its subsidiary got clinical trial approval for HB0043, a world-first bispecific antibody for hidradenitis suppurativa, advancing its innovative pipeline.
These are new positive developments that improve cash flow and pipeline prospects, though smaller than the profit forecast.

August 202624 Jul – 7 Oct 2026

▲4

Huahai's profit surges on API growth, procurement wins, and US recovery

Q1-Q3 profit forecast up 170-190% Huahai expects net profit for the first three quarters of 2026 to jump 170%-190% to 1.03-1.10 billion yuan, driven by API market expansion, domestic procurement share gains, and a turnaround in US finished drug sales. This directly boosts investor confidence and the stock's earnings outlook.
This is the biggest new financial catalyst, showing a sharp profit increase that likely drives the stock price up.
Reciceptimab approved for market Huahai's first-in-class IL-36R antibody Reciceptimab (Huayijing) received marketing approval in China for generalized pustular psoriasis. This strengthens its innovative drug pipeline and opens a new revenue stream, supporting long-term growth and valuation.
A new drug approval is a concrete pipeline win that can lift future earnings and investor sentiment.
Won bids for 4 products in national procurement Huahai won bids for four products in China's 12th national drug procurement, three of which were newly approved in Q2 2026. Winning these bids helps quickly expand domestic hospital sales and market share, though price cuts are typical in such programs.
Procurement wins directly boost domestic sales volume and are a key growth driver cited in the profit forecast.
US tariff refunds and HB0043 trial approval Huahai received over $10 million in US IEEPA tariff refunds, adding a one-time profit boost. Separately, its subsidiary got clinical trial approval for HB0043, a world-first bispecific antibody for hidradenitis suppurativa, advancing its innovative pipeline.
These are new positive developments that improve cash flow and pipeline prospects, though smaller than the profit forecast.

Latest24 Jul – 7 Oct 2026

▲4

Huahai's profit surges on API growth, procurement wins, and US recovery

Q1-Q3 profit forecast up 170-190% Huahai expects net profit for the first three quarters of 2026 to jump 170%-190% to 1.03-1.10 billion yuan, driven by API market expansion, domestic procurement share gains, and a turnaround in US finished drug sales. This directly boosts investor confidence and the stock's earnings outlook.
This is the biggest new financial catalyst, showing a sharp profit increase that likely drives the stock price up.
Reciceptimab approved for market Huahai's first-in-class IL-36R antibody Reciceptimab (Huayijing) received marketing approval in China for generalized pustular psoriasis. This strengthens its innovative drug pipeline and opens a new revenue stream, supporting long-term growth and valuation.
A new drug approval is a concrete pipeline win that can lift future earnings and investor sentiment.
Won bids for 4 products in national procurement Huahai won bids for four products in China's 12th national drug procurement, three of which were newly approved in Q2 2026. Winning these bids helps quickly expand domestic hospital sales and market share, though price cuts are typical in such programs.
Procurement wins directly boost domestic sales volume and are a key growth driver cited in the profit forecast.
US tariff refunds and HB0043 trial approval Huahai received over $10 million in US IEEPA tariff refunds, adding a one-time profit boost. Separately, its subsidiary got clinical trial approval for HB0043, a world-first bispecific antibody for hidradenitis suppurativa, advancing its innovative pipeline.
These are new positive developments that improve cash flow and pipeline prospects, though smaller than the profit forecast.